Shares of Thyrocare Technologies declined sharply by over 4% in early morning trade, even as the diagnostics major reported a strong set of Q3 FY26 consolidated numbers on a year-on-year basis.
In early trading, Thyrocare Technologies touched a low of ₹438.55 and a high of ₹469.00, compared with its previous close of ₹458.70. The stock opened at ₹463.00 before moving lower. Over a longer horizon, the counter remains well above its 52-week low of ₹219.33, though it is still below the 52-week high of ₹536.66.
For the December quarter of FY26, Thyrocare Technologies reported revenue growth of 17.8%, with consolidated revenue rising to ₹196 crore from ₹166 crore in the corresponding quarter last year. Operating performance improved at a faster pace, with EBITDA increasing 38.6% to ₹57.8 crore compared with ₹41.7 crore a year ago. This led to a notable expansion in EBITDA margin, which improved to 29.6% from 25.2% on a year-on-year basis.
Net profit for the quarter also showed strong momentum, climbing 51.8% to ₹29 crore from ₹19.1 crore in Q3 FY25.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
